Free Alerts   Login
Health Care › Surgical And Medical Instruments And Apparatus

ICAD Stock Price Correlated With iCAD Financials

ICAD Stock Price vs. Quarterly
ICAD
Income Statement
Cash Flow
Balance Sheet

ICAD Income Statement

Enable JavaScript and reload
Revenue, Net:
Revenue Per Share:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
Earnings Per Share, Diluted:
Earnings Per Share, Basic:
Shares Outstanding, Basic Avg:
Shares Outstanding, Diluted Avg:
Common Stock Shares Outstanding:

ICAD Cash Flow

Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Net Cash from Operations Per Share:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:

ICAD Balance Sheet

Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Portolan Capital Management
1,232,445 sh
-12,208 sh
-1%
$2,181
-$445
Vanguard Group
1,087,355 sh
31,510 sh
3%
$1,925
-$302
First Eagle Investment Management
679,525 sh
18,689 sh
3%
$1,203
-$191
Renaissance Technologies
522,190 sh
182,387 sh
54%
$1
Granahan Investment Management/Ma
426,409 sh
-468,760 sh
-52%
$755
-$1,134
Blackrock.
348,102 sh
-634 sh
0%
$617
-$119
Geode Capital Management
239,376 sh
18,562 sh
8%
$424
-$42
General American Investors Co
200,434 sh
 
$355
Deutsche Bank Ag\
173,787 sh
173,787 sh
NEW
$308
$308
Gwm Advisors
162,731 sh
-7,779 sh
-5%
$288
$10
Perritt Capital Management
130,266 sh
-45,900 sh
-26%
$231
-$141
Dimensional Fund Advisors
97,860 sh
-15,625 sh
-14%
$173
-$66
Morgan Stanley
84,834 sh
9,409 sh
12%
$151
-$8
Bridgeway Capital Management
74,600 sh
 
$132
State Street
72,135 sh
 
$128
Squarepoint Ops
60,919 sh
60,919 sh
NEW
$108
$108
Millennium Management
57,385 sh
22,817 sh
66%
$102
$29
Susquehanna International Group,
52,831 sh
35,531 sh
205%
$94
$57
Citadel Advisors
49,025 sh
47,525 sh
3168%
$86
$83
Schonfeld Strategic Advisors
48,900 sh
900 sh
2%
$87
$9
COMPANY PROFILE
Note 1 –

Organization and Business

iCAD, Inc. and subsidiaries (the “Company” or “iCAD”) is a global medical technology company providing innovative cancer detection and therapy solutions.

The Company operates in two segments: Cancer Detection (“Detection”) and Cancer Therapy (“Therapy”). In the detection segment, offered solutions include advanced artificial intelligence and image analysis workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the most prevalent cancers earlier, a comprehensive range of high-performance, upgradeable computer-aided detection systems and workflow solutions for digital breast tomosynthesis, full-field digital mammography, magnetic resonance imaging and computed tomography. In the Therapy segment, the Company offers the Xoft System, which is a cancer treatment platform technology incorporating a miniaturized, isotope-free radiation source. The Company’s commercial products are cleared with the United States Food and Drug Administration and various global regulatory agencies and use of iCAD’s products are reimbursable in the U.S. under federal and most third-party insurance programs. The Company sells its products throughout the world through its direct sales organization as well as through various OEM partners, distributors, technology platform partners, and resellers. See Note 14 of these consolidated financial statements for segment, major customer and geographical information.

The Company maintains its headquarters and a separate manufacturing facility in Nashua, New Hampshire, an operations, research, development, manufacturing and warehousing facility in San Jose, California, and an office in Lyon, France.

Free historical financial statements for iCAD Inc.. See how revenue, income, cash flow, and balance sheet financials have changed over 47 quarters since 2012. Compare with ICAD stock chart to see long term trends.

Data imported from iCAD Inc. SEC filings. Check original filings before making any investment decision.